InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $3.190 1.05 (49.07%)+
Announcement
Release
8 Apr 2026 8:21AM
Price at Release
$2.140
Full Release
download
Summary
Cogstate Limited, a leader in clinical trial endpoint data quality and digital cognitive assessments, released a business update for the quarter ending 31 March 2026. The company observed sustained demand across various Central Nervous System (CNS) fields, corroborating 1H26 trends. During 3Q26, sales contracts valued at $25.4 million were executed, bringing the 9-month total to $67.1 million. By 31 March 2026, contracted revenue for 2H26 was $29.1 million, and total contracted revenue for FY26 was $56.0 million, exceeding FY25's $53.1 million. For FY27, contracted revenue is $35.6 million, up from $27.0 million at the end of 2025. Cogstate offers solutions enabling accurate CNS measurement data for clinical trials and aims to provide validated digital cognitive tests for primary healthcare. Forward-looking statements indicate potential uncertainties due to factors outside Cogstate's control.
Key Points
  • Cogstate reported $25.4 million in sales contracts for 3Q26.
  • Total sales contracts for 9 months ending March 2026 were $67.1 million.
  • Contracted revenue for 2H26 is $29.1 million.
  • FY26 contracted revenue is $56.0 million, surpassing FY25's $53.1 million.
  • Contracted revenue for FY27 is expected to be $35.6 million.
  • Cogstate specializes in CNS measurement solutions for clinical trials.
  • The company provides digital cognitive assessments in the healthcare market.
  • Forward-looking statements highlight potential variances due to uncontrollable factors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.